LATEST HEADLINES

60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections
LEARN MORE

Developing therapeutic innovations that can significantly improve and extend people’s lives.

In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of infectious diseases. In 2022, we are continuing this mission with a broader focus on product development and commercialization for infectious diseases.

Responding to COVID-19 infections

Finding solutions to enhance response to COVID-19 infections

We are advancing clinical trials for a therapy that may potentially accelerate symptom relief.

Escalating malaria care around the world

Escalating malaria care to people in need around the world

Advancing therapies for the prevention of malaria.

Meeting the global dengue endemic

Meeting the global challenges of dengue

There is an unmet medical need for dengue fever treatment.

For the Investment Community

For the investment community

We are committed to serving the best interests of our investors.

Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by infectious diseases worldwide.

90,000,000+

Cases and 1 Million+ deaths in the U.S. from COVID-19 infections

627,000

Annual deaths from malaria globally

125,000,000

Travelers to malaria endemic regions per annum

390,000,000

Annual dengue infections globally

202-327-5422

1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036